| Home | E-Submission | Sitemap | Editorial Office |  
Korean J Urol Oncol > Volume 7(3); 2009 > Article
The Korean Journal of Urological Oncology 2009;7(3): 125-130.
전립선암에서 남성호르몬박탈요법의 최신 개념: 남성호르몬 수용체를 표적하는 새로운 접근법들
곽 철
서울대학교 의과대학 비뇨기과학교실
Current Concepts in Androgen Deprivation Therapy for Prostate Cancer: New Approaches to Target Androgen Receptor
Cheol Kwak
Department of Urology, Seoul National University College of Medicine, Seoul, Korea
Published online: December 1, 2009.
Prostate specific antigen (PSA) is still prognostic factor in hormone-refractory prostate cancer (HRPC), and it means activated androgen receptor (AR) is needed even in this situation. Actually many evidences which show AR plays an important role for proliferation in HRPC and HRPC is under the control of androgen lead a new horizon of view. Recently, we have noticed that HRPC can produce endogenous androgen by classic and backdoor pathway and maintain high intracellular dihydrotestosterone (DHT) level. Thus, ketoconazole has been refocused, and new drugs which can block androgenic steroid synthetic pathway such as abiraterone acetate are becoming newly prominent. Other drugs to target AR is still under investigation and they showed promising initial results. Even argue that ‘hormone-refractory’ is misnomer has been raised. (Korean J Urol Oncol 2009;7:125-130)
Key Words: Androgen deprivation therapy; Prostate cancer; Androgen receptor
Editorial Office
Department of Urology, Chung-Ang University Hospital
102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-1819   Fax: +82-2-6294-1406   E-mail: journal@kjuo.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Urological Oncology Society and The Korean Prostate Society.                 Developed in M2PI
Close layer
prev next